Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6199107 | Ophthalmology | 2016 | 10 Pages |
Abstract
Retinal detachment is an important cause of visual loss. Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, are the only means to repair retinal detachment and restore vision. However, surgical failure rates may be as high as 20%, and visual outcomes continue to vary secondary to multiple processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular folds, and, ultimately, photoreceptor death. Therefore, pharmacotherapies are being sought to aid the success rates of modern surgical techniques and reduce or slow the degeneration of photoreceptors during retinal detachment. This review discusses potential therapeutic avenues that aid in retinal reattachment, reduce the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against photoreceptor cell death.
Keywords
RRDFDAPDGFRαmTORTGFβMCP-1PDGFROPRPEAIFUS Food and Drug Administrationretinal pigment epitheliumTransforming growth factor βtumor necrosis factor αTUNELRhegmatogenous retinal detachmentROP, Retinopathy of prematurityPVRapoptosis-inducing factorVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)platelet-derived growth factorTNF-αterminal deoxynucleotidyl transferase-mediated dUTP nick-end labelingmammalian target of rapamycinProliferative vitreoretinopathyRIPmonocyte chemoattractant protein-1Receptor-interacting proteinplatelet-derived growth factor receptor α
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Thomas J. MD, PhD, Cagri G. MD, PhD, David N. MD, PhD,